MK-0249 Completed Phase 2 Trials for Alzheimer's Disease (AD) Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00420420MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)